From the Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan (Pan).
The Division of Nephrology, Department of Internal Medicine (Pan, Sun), Keelung Chang Gung Memorial Hospital, Keelung, Taiwan.
Arch Pathol Lab Med. 2022 Nov 1;146(11):1353-1363. doi: 10.5858/arpa.2021-0411-OA.
CONTEXT.—: Critically ill patients with acute kidney injury (AKI) requiring renal replacement therapy (RRT) have a poor prognosis. Several urinary AKI biomarkers have been proposed to predict renal recovery, but with limited discriminatory ability.
OBJECTIVE.—: To validate the predictive performances of novel biomarkers to identify which critical patients with AKI may successfully wean from RRT.
DESIGN.—: We prospectively recorded and analyzed clinical variables at several time points: (1) before starting RRT, (2) at the time of weaning off RRT, and (3) 24 hours after stopping RRT. A total of 140 critically ill patients who received RRT at a multicenter referral hospital from August 2016 to January 2019 were enrolled. The outcomes of interest were the ability to wean from RRT and 90-day mortality.
RESULTS.—: The 90-day mortality rate was 13.6% (19 of 140), and 47.9% (67 of 140) of the patients were successfully weaned from RRT. Cluster analysis showed that the following biomarkers were correlated with estimated glomerular filtration rate at the time of weaning off RRT: urinary neutrophil gelatinase-associated lipocalin, kidney injury molecule 1, hemojuvelin, C-C motif chemokine ligand 14, interleukin 18, and liver-type fatty acid-binding protein (L-FABP). Among these, urinary L-FABP/creatinine (uL-FABP/Cr) at the time of weaning off RRT showed the best predictive performance for mortality (area under the receiver operating characteristic curve = 0.79). Taking mortality as a competing risk, Cox proportional hazards analysis indicated that a low uL-FABP/Cr (log) level was an independent prognostic factor for weaning from RRT (subdistribution hazard ratio, 0.35; P = .01).
CONCLUSIONS.—: uL-FABP/Cr at the time of weaning off RRT could predict weaning from RRT and 90-day mortality.
急性肾损伤(AKI)需接受肾脏替代治疗(RRT)的危重症患者预后不良。已有多种尿 AKI 生物标志物被提出用于预测肾功能恢复,但预测能力有限。
验证新型生物标志物预测 AKI 患者能否成功脱机的性能。
前瞻性地记录和分析了多个时间点的临床变量:(1)开始 RRT 之前,(2)脱机时,以及(3)停止 RRT 后 24 小时。2016 年 8 月至 2019 年 1 月,我们在一家多中心转诊医院招募了 140 名接受 RRT 的危重症患者。主要结局是能否脱机以及 90 天死亡率。
90 天死亡率为 13.6%(19/140),47.9%(67/140)的患者成功脱机。聚类分析显示,脱机时与估计肾小球滤过率相关的生物标志物包括尿中性粒细胞明胶酶相关脂质运载蛋白、肾损伤分子 1、血红素结合蛋白、C-C 基序趋化因子配体 14、白细胞介素 18 和肝型脂肪酸结合蛋白(L-FABP)。其中,脱机时尿 L-FABP/肌酐(uL-FABP/Cr)预测死亡率的表现最佳(接受者操作特征曲线下面积=0.79)。考虑到死亡率是一种竞争风险,Cox 比例风险分析表明,uL-FABP/Cr 水平较低是脱机的独立预后因素(亚分布危险比,0.35;P=0.01)。
脱机时 uL-FABP/Cr 可预测脱机和 90 天死亡率。